4-(肼基羰基)苯甲酰胺 | 22590-92-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(肼基羰基)苯甲酰胺
• 中文别名: 4-(氨基氨基甲酰)苯甲酰胺；4-(肼羰基)苯甲酰胺
• 英文名称: 4-(hydrazinocarbonyl)benzamide
• 英文别名: 4-carbamoylbenzoic acid hydrazide；4-(carbohydrazide)benzamide；4-(Hydrazinecarbonyl)benzamide
• CAS: 22590-92-7
• 化学式: C₈H₉N₃O₂
• mdl: MFCD03422938
• 分子量: 179.178
• InChiKey: DEDIISHJHWEMEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  98.2
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  4-(肼基羰基)苯甲酰胺 在 氯化铵 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 4-(2-((4-aminophenyl)sulfonyl)hydrazine-1-carbonyl)benzamide
  参考文献：
  名称：

  [EN] BIFUNCTIONAL COMPOUND USING UBR BOX DOMAIN-BINDING LIGAND
  [FR] COMPOSÉ BIFONCTIONNEL UTILISANT UN LIGAND LIANT LE DOMAINE DE BOÎTE UBR
  [KO] UBR 박스 도메인 결합 리간드를 이용한 이중기능성 화합물

  摘要：

  본 명세서에서 개시하는 내용은 UBR 박스 도메인 결합 리간드를 이용한 이중기능성(bifunctional) 화합물에 관한 것이다. 상기 UBR 박스 도메인은 N-말단 경로 법칙(N-end rule pathway)의 UBR(Ubiquitin protein ligase E3 component n-recognin)단백질 내에 공통적으로 존재하는 도메인이다. 이 때 상기 UBR 박스 도메인은 기질(substrate)이 결합하는 도메인으로 알려져 있다. 상기 UBR 박스 도메인은 기질의 N-말단 잔기에 결합하여 기질에 멀티 유비퀴틴 사슬을 형성하는데 필수적이며, 기질은 이 과정을 통해 분해된다고 알려져 있다. 이러한 UBR 박스 도메인의 기능을 이용하는 UBR 박스 도메인 리간드를 이용한 이중기능성(bifunctional) 화합물을 이용해 원하는 타겟 단백질(또는 펩타이드)을 보다 효과적으로 분해시키도록 유도할 수 있다.

  公开号：

  WO2023074936A1
• 作为产物：
  描述：

  4-氨基甲酰苯甲酸甲酯 在 一水合肼 作用下， 生成 4-(肼基羰基)苯甲酰胺
  参考文献：
  名称：

  作为 ERRγ 激动剂的简单酚酰胺的设计、合成和评价

  摘要：

  在此，我们报告了一系列基于腙先导分子的简单酚酰胺 ERRγ 激动剂的设计和合成。我们在该系列中的构效关系研究揭示了分子的苯酚部分是活性所必需的。尝试用更合适的化学类型取代腙导致了一种简单的酰胺作为可行的替代品。微分氢-氘交换实验用于帮助理解与 ERRγ 结合的​​结构基础，并有助于开发更有效的配体。

  DOI：

  10.1016/j.bmcl.2018.03.019

文献信息

• Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
  申请人：D'Sidocky Neil R.

  公开号：US20080242694A1

  公开（公告）日：2008-10-02

  Provided herein are Heterocyclic Compounds having the following structure: wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

  本文提供具有以下结构的杂环化合物： 其中R1、R2、X、Y和Z如本文所定义，包含有效量杂环化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、代谢性疾病以及通过给予患者需要的有效量杂环化合物来抑制激酶途径治疗或预防的疾病的方法。
• [EN] PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE<br/>[FR] PIPÉRIDINYLPYRAZOLOPYRIMIDINONES ET LEUR UTILISATION
  申请人：BAYER PHARMA AG

  公开号：WO2016071216A1

  公开（公告）日：2016-05-12

  The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代哌啶基吡唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者的急性和复发性出血，其中出血与从重经期出血、产后出血、出血性休克、出血性膀胱炎、胃肠道出血、创伤、手术、移植、中风、肝脏疾病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。
• Palladium-Catalyzed Chemoselective Monoarylation of Hydrazides for the Synthesis of [1,2,4]Triazolo[4,3-<i>a</i>]pyridines
  作者：Andreas Reichelt、James R. Falsey、Robert M. Rzasa、Oliver R. Thiel、Michal M. Achmatowicz、Robert D. Larsen、Dawei Zhang

  DOI：10.1021/ol902868q

  日期：2010.2.19

  efficient and convenient method for the synthesis of [1,2,4]triazolo[4,3-a]pyridines was exemplified by the synthesis of 20 analogues bearing a variety of substituents at the 3-position. The methodology involves a palladium-catalyzed addition of hydrazides to 2-chloropyridine, which occurs chemoselectively at the terminal nitrogen atom of the hydrazide, followed by dehydration in acetic acid under microwave

  合成[1,2,4]三唑并[4,3- a ]吡啶的一种有效而方便的方法，是通过合成20个在3位带有取代基的类似物来举例说明的。该方法包括将钯催化的酰肼加成至2-氯吡啶，其在酰肼的末端氮原子上发生化学选择性，然后在微波辐射下于乙酸中脱水。
• MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150211073A1

  公开（公告）日：2015-07-30

  Use of at least an MDM2 gene panel, preferably a four gene MDM2 gene panel, as a biomarker for predicting the response to a MDM2 antagonist.

  至少使用一个MDM2基因面板，最好是一个四基因MDM2基因面板，作为预测对MDM2拮抗剂反应的生物标志物。
• 1,2,4-TRIAZOLE CARBOXYLIC ACID DERIVATIVES AS MODULATORS OF MGLUR5
  申请人：GRANBERG Kenneth

  公开号：US20090111811A1

  公开（公告）日：2009-04-30

  The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

  本发明涉及新型化合物，其制备方法以及这些新型化合物在治疗中的应用和包含这些新型化合物的药物组合物。